Patents Issued in July 26, 2016
  • Concentration of the urea solution in a process for the synthesis of urea
    Patent number: 9399617
    Abstract: A process and a related plant for the synthesis of urea, where a solution (13) comprising urea is obtained in a synthesis section (10), said solution is treated in a recovery section (14), and an aqueous solution (15) comprising mainly urea and water, which is obtained from said recovery section, is concentrated by means of contact with a water-selective membrane.
    Type: Grant
    Filed: July 3, 2013
    Date of Patent: July 26, 2016
    Assignee: Casale SA
    Inventor: Andrea Scotto
  • High purity electrolytic sulfonic acid solutions
    Patent number: 9399618
    Abstract: Disclosed is a solution for an electrochemical process, the solution containing a sulfonic acid and having a low concentration of sulfur compounds, either low or high valence, that are susceptible to reduction and which is intended for use in electrodeposition, batteries, conductive polymers and descaling processes.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: July 26, 2016
    Assignee: Arkema Inc.
    Inventors: Nicholas M. Martyak, Martin Nosowitz, Gary S. Smith, Patrick Kendall Janney, Jean-Marie Ollivier
  • Sulfamoylbenzamide derivatives as antiviral agents against HBV infection
    Patent number: 9399619
    Abstract: Pharmaceutical compositions of the invention comprise sulfamoylbenzamide derivative useful as pregenomic RNA encapsidation inhibitors, useful for the treatment of Hepatitis B virus (HBV) infection.
    Type: Grant
    Filed: June 29, 2012
    Date of Patent: July 26, 2016
    Assignees: Baruch S. Blumberg Institute, Drexel University
    Inventors: Ju-Tao Guo, Xiaodong Xu, Timothy M. Block
  • Process for preparing 3-methylsulfonylpropionitrile
    Patent number: 9399620
    Abstract: The present invention relates to processes for preparing 3-methylsulfonylpropionitrile. The processes provide a good yield and a good purity of the final product and provide a controllable reaction. The present invention also relates to a crystalline form of 3-methylsulfonylpropionitrile having X-ray diffraction peaks at 13.9±0.1, 19.2±0.1, 20.0±0.1, 22.5±0.1, 23.2±0.1, 25.7±0.1, 28.1±0.1, 29.9±0.1, and 30.6±0.1 degrees 2?, and wherein the most intense peak is the peak at 13.9±0.1 degrees 2?.
    Type: Grant
    Filed: April 29, 2015
    Date of Patent: July 26, 2016
    Assignee: OLATEC THERAPEUTICS LLC
    Inventors: Joseph P. St. Laurent, Gerald S. Jones, David M. Bresse
  • Process for preparing substituted indole derivatives
    Patent number: 9399621
    Abstract: The present invention relates to a process for preparing substituted indole derivatives. More particularly, the invention refers to a new method to synthesize indole-derivatives by oxidative C—H-functionalization.
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: July 26, 2016
    Assignee: STUDIENGESELLSCHAFT KOHLE MBH
    Inventors: Martin Klussmann, Naeem Gulzar
  • Nitroxide hydroxylamine and phenylenediamine combinations as polymerization inhibitors for ethylenically unsaturated monomer processes
    Patent number: 9399622
    Abstract: Polymerization inhibitor compositions are provided. The polymerization inhibitor compositions may include at least one hydroxylamine of a nitroxide and at least one phenylenediamine. Methods of inhibiting the unwanted polymerization of monomers are also provided. The methods include adding the presently disclosed polymerization inhibitor compositions to a fluid containing the monomers. The monomers may be ethylenically unsaturated monomers, such as acrylic acid, methacrylic acid, acrylonitrile, methacrylonitrile, acrolein, methacrolein, acrylate, methacrylate, acrylamide, methacrylamide, vinyl acetate, butadiene, ethylene, propylene, and styrene.
    Type: Grant
    Filed: December 3, 2013
    Date of Patent: July 26, 2016
    Assignee: ECOLAB USA INC.
    Inventor: David Youdong Tong
  • Quinoline derivatives and their use in neurodegenerative diseases
    Patent number: 9399623
    Abstract: The present invention relates to quinoline compounds, and pharmaceutically acceptable compositions thereof, useful as antagonists of P2X7, and for the treatment of P2X7-related disorders.
    Type: Grant
    Filed: June 4, 2015
    Date of Patent: July 26, 2016
    Assignee: Merck Patent GmbH
    Inventors: Srinivasa R. Karra, Yufang Xiao, Jeyaprakashnarayanan Seenisamy, Jayashankaran Jayadevan
  • Process for preparing (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate
    Patent number: 9399624
    Abstract: A process for preparation of (1S)-1-phenyl-3,4-dihydro-2(1H)-isoquinoline-carboxylate (Formula I), comprising reacting (1S)-1-phenyl-3,4-dihydro-2(1H)isoquinoline (Formula II) with carbon dioxide and an alkylating agent R-LG in the presence of a base to obtain the compound of Formula I in an organic solvent. In Formula I and II, R is an alkyl or a substituted alkyl; LG is a leaving group.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: July 26, 2016
    Assignees: Shanghai Jingxin Biomedical Co., Ltd., Shangyu Jingxin Pharmaceutical Co., Ltd.
    Inventors: Yue Huang, Fei Zheng
  • Acridone compounds
    Patent number: 9399625
    Abstract: (A1) A class of acridone compounds has been discovered that exhibits chemosensitizing and antiparasitic activity. Described herein are pharmaceutical compositions and methods for their use to treat parasitic infections, such as malaria and toxoplasmosis, and to sensitize resistant cells, such as multidrug resistant cells to other therapeutic agents. The pharmaceutical compositions and methods may also be used to treat and/or prevent psychotic diseases such as schizophrenia.
    Type: Grant
    Filed: February 16, 2015
    Date of Patent: July 26, 2016
    Assignees: Oregon Health & Science University, The United States of America
    Inventors: Michael K. Riscoe, Rolf W. Winter, Jane X. Kelly, David J. Hinrichs, Martin J. Smilkstein
  • 2-thiopyrimidinones
    Patent number: 9399626
    Abstract: Myeloperoxidase inhibitors, pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, cardiovascular conditions.
    Type: Grant
    Filed: June 9, 2014
    Date of Patent: July 26, 2016
    Assignee: Pfizer Inc.
    Inventors: Philip A. Carpino, Edward L. Conn, Robert L. Dow, Matthew S. Dowling, David Hepworth, Daniel Wei-Shung Kung, Suvi Orr, Benjamin N. Rocke, Roger B. Ruggeri, Matthew F. Sammons, Joseph S. Warmus, Yan Zhang
  • Substituted macrocyclic compounds having proteasome inhibitory activity
    Patent number: 9399627
    Abstract: The disclosure provides for novel compounds which have proteasome inhibitory activity, pharmaceutical compositions made thereof, and methods of use thereof to treat various disorders, including cancer and nonmalignant tumors.
    Type: Grant
    Filed: June 14, 2013
    Date of Patent: July 26, 2016
    Assignee: The Regents of the University of California
    Inventor: Michael C. Pirrung
  • 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity
    Patent number: 9399628
    Abstract: Compounds of the formula where the variables have the meaning defined in the specification have analgesic and/or immunostimulant effect in mammals.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: July 26, 2016
    Assignee: Allergan, Inc.
    Inventors: Bertrand Leblond, Eric Beusoleil, Thierry Taverne, John E. Donello
  • Process for the manufacture of 3-oxo-tetrahydrofuran
    Patent number: 9399629
    Abstract: This invention relates to a novel method for the preparation of 3-oxo-tetrahydrofuran comprising oxidizing 3-hydroxy-tetrahydrofuran in the presence of a catalytic amount of 2,2,6,6-tetramethyl-piperidine-N-oxyl (TEMPO) with trichloroisocyanuric acid.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: July 26, 2016
    Assignee: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Lidong Xing, Weitong Dong, Jun Lu, Ulrich Scholz, Jun Yan, Jinsong Yang
  • Process for preparing benzofuran-2-carboxamide derivatives
    Patent number: 9399630
    Abstract: Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of benzofuran-2-carboxamide derivatives and their intermediates, or a pharmaceutically acceptable salt thereof, in high yield and purity. Provided particularly herein are novel, commercially viable and industrially advantageous processes for the preparation of vilazodone or a pharmaceutically acceptable salt thereof in high yield and purity. Provided also herein is an improved and commercially viable process for the preparation of 3-(4-hydroxybutyl)-1H-indole-5-carbonitrile, in high yield and purity, using novel intermediate compound 3-(4-hydroxybutyryl)-1H-indole-5-carbonitrile.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: July 26, 2016
    Assignee: Symed Labs Limited
    Inventors: Mohan Rao Dodda, Jithender Aadepu
  • Polyphenol proteasome inhibitors, synthesis, and methods of use
    Patent number: 9399631
    Abstract: The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: July 26, 2016
    Assignees: UNIVERSITY OF SOUTH FLORIDA, MCGILL UNIVERSITY, THE HONG KONG POLYTECHNIC UNIVERSITY
    Inventors: Q. Ping Dou, Tak-Hang Chan, David M. Smith
  • Process for producing a solid oxidic material
    Patent number: 9399632
    Abstract: The present invention relates to a process for producing a porous solid oxidic material from a hydrogel of the oxidic material and to the porous solid oxidic material as such.
    Type: Grant
    Filed: February 4, 2014
    Date of Patent: July 26, 2016
    Assignee: BASF SE
    Inventors: Johann Martin Szeifert, Michael Kutschera
  • Photoinitiators
    Patent number: 9399633
    Abstract: The present invention provides novel photoinitiators for polyurethane formation, in which a photoinitiator moiety and a tertiary amine are incorporated into the photoinitiator structure, and thus the polyurethane polymer.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: July 26, 2016
    Assignee: Coloplast A/S
    Inventors: Niels Joergen Madsen, Petr Sehnal, Christian B. Nielsen, David George Anderson
  • Compositions and methods for the treatment of depression
    Patent number: 9399634
    Abstract: The invention relates to the compounds of formula I or its pharmaceutical acceptable salts, as well as polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, and methods for treating or preventing depression may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, intravenous, parenteral administration, syrup, or injection. Such compositions may be used to treatment of major depressive disorder (MDD), anxiety, neurological diseases, general anxiety disorder, social phobia, panic disorder, vasomotor symptoms, diabetic neuropathy, epilepsy, bipolar disorder, migraine, schizophrenia, cancer, menopause, HIV and familial adenomatous polyposis.
    Type: Grant
    Filed: February 1, 2013
    Date of Patent: July 26, 2016
    Assignee: CELLIX BIO PRIVATE LIMITED
    Inventor: Mahesh Kandula
  • Pyrazole derivative
    Patent number: 9399635
    Abstract: Provided is a novel therapeutic means for Alzheimer's disease. In particular, provided is a compound represented by the following general formula (I): [wherein Ar1 represents 2-methoxy-4-(2-pyridylmethoxy)phenyl etc. and Ar2 represents a 1H-indol-6-yl group etc.] or a salt thereof.
    Type: Grant
    Filed: April 11, 2012
    Date of Patent: July 26, 2016
    Assignee: GREEN TECH CO., LTD.
    Inventors: Hachiro Sugimoto, Michiaki Okuda, Takashi Takahashi, Ichiro Hijikuro, Hidetaka Suzuki, Shinichi Nakayama
  • Substituted dipyridylamines and uses thereof
    Patent number: 9399636
    Abstract: The present invention provides for compounds of Formula I and various embodiments thereof, and compositions comprising compounds of Formula I and various embodiments thereof. In compounds of Formula I, the groups R1, R2, R3, R4, R5, R6, m, n and the C-linked Ring have the meaning as described herein. The present invention also provides for methods of using compounds of Formula I and compositions comprising compounds of Formula I as DLK inhibitors and for treating neurodegeneration diseases and disorders.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: July 26, 2016
    Assignee: Genentech, Inc.
    Inventors: Frederick Cohen, Malcolm Huestis, Cuong Ly, Snahel Patel, Michael Siu, Xianrui Zhao
  • Substituted heteroaryl compounds and methods of use
    Patent number: 9399637
    Abstract: The present invention provides novel heteroaryl compounds, pharmaceutical acceptable salts and formulations thereof useful in preventing, treating or lessening the severity of a protein-mediated disease. The invention also provides pharmaceutically acceptable compositions comprising such compounds and methods of using the compositions in the treatment of protein kinase-mediated disease.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 26, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Minxiong Li, Xiaobo Li, Tao Zhang, Yanjun Wu
  • Substituted pyridine compounds as CRAC modulators
    Patent number: 9399638
    Abstract: The present invention relates to compounds described herein Formula (I) and pharmaceutical acceptable salts thereof, which modulate the activity of calcium release-activated calcium (CRAC) channel. The invention also describes the compounds of Formula (I) and pharmaceutical compositions containing such compounds thereof for treating, managing, and/or lessening the severity of diseases, disorders, syndromes or conditions associated with the modulation of calcium release-activated calcium (CRAC) channel.
    Type: Grant
    Filed: May 1, 2013
    Date of Patent: July 26, 2016
    Assignee: LUPIN LIMITED
    Inventors: Nageswara Rao Irlapati, Zubair Abdul Wajid Shaikh, Vijay Pandurang Karche, Gokul Keruji Deshmukh, Neelima Sinha, Venkata P. Palle, Rajender Kumar Kamboj
  • Substituted azaindole compounds, salts, pharmaceutical compositions thereof and methods of use
    Patent number: 9399639
    Abstract: The present invention provides substituted azaindole prodrugs, methods of making said prodrugs, pharmaceutical compositions of said prodrugs and methods of using said prodrugs and pharmaceutical compositions thereof to treat or prevent diseases or disorders such as cancer.
    Type: Grant
    Filed: August 26, 2013
    Date of Patent: July 26, 2016
    Assignees: CALITOR SCIENCES, LLC, SUNSHINE LAKE PHARMA CO., LTD.
    Inventors: Ning Xi, Tingjin Wang, Yin Tang, Mingming Sun, Qian Wang
  • Substituted pyrrolo[2,3-c]pyridines and pyrazolo[3,4-c]pyridines as BET protein inhibitors
    Patent number: 9399640
    Abstract: The present invention relates to compounds represented by the general Formula I which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: July 26, 2016
    Assignee: Incyte Corporation
    Inventors: Eddy W. Yue, Andrew P. Combs, Brent Douty
  • Pyrrolobenzodiazepines as unsymmetrical dimeric PBD compounds for inclusion in targeted conjugates
    Patent number: 9399641
    Abstract: A compound with the formula I wherein: R2 is of formula II where Q is selected from OH, SH and NRN, and RN is selected from H, methyl and ethyl, as well as drug-linkers and drug-conjugates made from this compound.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: July 26, 2016
    Assignee: MEDIMMUNE LIMITED
    Inventor: Philip Wilson Howard
  • Pharmaceutical intermediates and methods for preparing the same
    Patent number: 9399642
    Abstract: A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 26, 2016
    Inventor: William Allen Boulanger
  • Pharmaceutical intermediates and methods for preparing the same
    Patent number: 9399643
    Abstract: A pharmaceutical intermediate including a first indole moiety which is associated with an optionally carboxylated hexahydroazepino moiety, an optionally carboxylated azonane moiety, or a second, optionally carboxylated indole moiety, having an alkyl, allyl, phenylallyl, cinnamyl, alkenyl, and/or alkyl-alkenyl substituent pendant from a nitrogen atom of the same.
    Type: Grant
    Filed: March 28, 2014
    Date of Patent: July 26, 2016
    Inventor: William Allen Boulanger
  • [1,3] dioxolo [4,5-G] quinoline-6(5H)thione derivatives as inhibitors of the late SV40 factor (LSF) for use in treating cancer
    Patent number: 9399644
    Abstract: The present invention relates generally to methods, compounds and/or compositions suitable for inhibiting, preventing and/or treating cancer, e.g. hepatocellular carcinoma (HCC). In some embodiments, the invention relates to the use of small-molecule compounds to inhibit, prevent and/or treat expression of the transcription factor Late SV40 Factor (LSF) for treatment of HCC or other cancer types.
    Type: Grant
    Filed: June 12, 2015
    Date of Patent: July 26, 2016
    Assignee: Trustees of Boston University
    Inventors: Scott E. Schaus, Ulla Hansen, Joshua A. Bishop
  • Inhibitors of HIV replication
    Patent number: 9399645
    Abstract: Compounds of formula (I) and pharmaceutical compositions thereof: wherein A1 A2 and A3 are each independently selected from the group consisting of N and CR3, wherein R1 is an optionally substituted heterocyclyl or an optionally substituted —(C1-6)alkyl-heterocyclyl, R2 is an optionally substituted aryl or an optionally subsisted heteroaryl, R4 is an optionally substituted aryl, an optionally substituted heterocyclyl or an optionally substituted heteroaryl, useful as an inhibitor of HIV replication.
    Type: Grant
    Filed: December 19, 2012
    Date of Patent: July 26, 2016
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Claudio Sturino, Pierre Beaulieu, Patrick Deroy, Martin Duplessis, Clint James, Jean-Eric Lacoste, Joannie Minville, Louis Morency, Sébastien Morin, Bruno Simoneau, Martin Tremblay
  • Estrogen receptor modulators and uses thereof
    Patent number: 9399646
    Abstract: Described herein are compounds that are estrogen receptor modulators. Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well methods of using such estrogen receptor modulators, alone and in combination with other compounds, for treating diseases or conditions that are mediated or dependent upon estrogen receptors.
    Type: Grant
    Filed: September 15, 2011
    Date of Patent: July 26, 2016
    Assignee: Genentech, Inc.
    Inventors: Nicholas D. Smith, Mehmet Kahraman, Steven P. Govek, Johnny Y. Nagasawa, Andiliy G. Lai, Jackaline D. Julien, Mark R. Herbert, Celine Bonnefous, Karensa L. Douglas
  • Proteasome activity modulating compounds
    Patent number: 9399647
    Abstract: The present invention is directed to compounds having the Formula (I), (Ia) or (Ib), compositions thereof and methods for the treatment of a condition associated with a dysfunction in proteostasis.
    Type: Grant
    Filed: July 17, 2014
    Date of Patent: July 26, 2016
    Assignee: Proteostasis Therapeutics, Inc.
    Inventors: Robert J. Chambers, Megan Foley, Bradley Tait
  • Isothiazolopyridinones useful for the treatment of (inter alia) cystic fibrosis
    Patent number: 9399648
    Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.
    Type: Grant
    Filed: June 27, 2014
    Date of Patent: July 26, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventor: Alejandra Gallardo-Godoy
  • Compounds for treating spinal muscular atrophy
    Patent number: 9399649
    Abstract: Provided herein are compounds, compositions thereof and uses therewith for treating spinal muscular atrophy.
    Type: Grant
    Filed: January 25, 2013
    Date of Patent: July 26, 2016
    Assignee: PTC Therapeutics, Inc.
    Inventors: Guangming Chen, Amal Dakka, Gary Mitchell Karp, Chunshi Li, Jana Narasimhan, Nikolai Naryshkin, Marla L. Weetall, Ellen Welch, Xin Zhao
  • Method for producing salts having monofluoro-tricyanoborate anions
    Patent number: 9399650
    Abstract: The invention relates to a method for producing alkali metal salts having monofluoro-tricyanoborate anions from alkali metal tetrafluoroborates.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: July 26, 2016
    Assignee: Merck Patent GmbH
    Inventors: Nikolai (Mykola) Ignatyev, Jan Arke Peter Spenger, Johannes Landmann, Maik Finze
  • Inhibitors of catechol O-methyl transferase and their use in the treatment of psychotic disorders
    Patent number: 9399651
    Abstract: The present invention relates to 4-pyridinone compounds which are inhibitors of catechol O-methyltransferase (COMT), and are useful in the treatment and prevention of neurological and psychiatric disorders and diseases in which COMT enzyme is involved. The present invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which COMT is involved.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: July 26, 2016
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Scott Wolkenberg, James C. Barrow, Michael S. Poslusney, Scott T. Harrison, Wesley B. Trotter, James Mulhearn, Kausik K. Nanda, Peter J. Manley, Zhijian Zhao, Jeffrey W. Schubert, Nathan R. Kett, Amy Zartman
  • Synthetic route to pactamycin and pactamycin analogs
    Patent number: 9399652
    Abstract: Methods and intermediates useful for making compounds of Formula (I) are described, including a general method of making an alpha, beta-diamino ketone by reacting an imine with a 2-amino-substituted 1,3-dicarbonyl in a Mannich addition reaction to produce said alpha,beta-diamino ketone.
    Type: Grant
    Filed: January 23, 2014
    Date of Patent: July 26, 2016
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Jeffrey Johnson, Justin Malinowski, Robert Sharpe
  • Methods and systems for preparing irreversible inhibitors of protein tyrosine phosphatases
    Patent number: 9399653
    Abstract: Described herein are the preparation and use of novel bromo-phosphonomethylphenylalanine amino acid derivatives (BrPmp) and BrPmp-containing peptides as specific, irreversible protein tyrosine phosphatase inhibitors, which are suitable for application in peptide synthesis. These derivatives are particularly advantageous since their synthesis is both easy and scalable, and they are suitable for peptide synthesis. The BrPmp derivatives described herein can be appropriately protected to allow for solid phase peptide synthesis (SPPS) and incorporation into peptides for preparation of protein tyrosine phosphatase inhibitors and inhibitor libraries. The peptides and peptide libraries can be used to identify new protein tyrosine phosphatase specific sequences and profile protein tyrosine phosphatase activity in cell lysates, diagnostic samples and biopsy samples.
    Type: Grant
    Filed: March 3, 2011
    Date of Patent: July 26, 2016
    Assignee: The Governors of the University of Alberta
    Inventors: Christopher Warren Cairo, Naresh Singh Tulsi, Alan Michael Downey
  • Iridium-based complexes for ECL
    Patent number: 9399654
    Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 26, 2016
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Christoph Seidel
  • Catalytic glycosylation with designer thioglycoside and novel protecting groups for same and for synthesis of oligosaccharides
    Patent number: 9399655
    Abstract: A catalytic glycosylation method comprising: installing thioether to an anomeric carbon of a carbohydrate; and catalytically activating the thioether with a non-oxophilic Lewis acid. The thioether may comprise an anomerically stable thioether leaving group. The catalytic glycosylation method may further comprise: utilizing an acid-sensitive ester protecting group as permanent protecting group or using a reactivity-based one-pot glycosylation that employs a single-component catalyst to accelerate an oligosaccharide assembly process. A protecting group to mask hydroxyl functionalities in the production of oligosaccharides, natural products or any molecule having a hydroxyl group comprising an acid-labile ester protecting group.
    Type: Grant
    Filed: June 6, 2013
    Date of Patent: July 26, 2016
    Assignee: University of Pittsburgh—Of The Commonwealth System of Higher Education
    Inventor: Xinyu Liu
  • Compound, method for producing same, and use of same
    Patent number: 9399656
    Abstract: A compound represented by the following Structural Formula (A) or a salt thereof. The compound or the salt thereof is suitably produced from a microorganism belonging to the genus Saccharothrix and can be suitably used as a prostaglandin production inhibitor.
    Type: Grant
    Filed: April 29, 2014
    Date of Patent: July 26, 2016
    Assignee: Microbial Chemistry Research Foundation
    Inventors: Koichi Nakae, Fukiko Kojima
  • Chemiluminescent methods and reagents for analyte detection
    Patent number: 9399657
    Abstract: The present invention relates to chemiluminescent method and regent to detect analyte. One aspect of the current invention relates to using enzyme substrate that can be cleaved by target enzyme to release chemiluminescent compound giving light signal for the detection of varieties of target enzymes. Another aspect of the current invention relates to use chemiluminescent enzyme coupled with analyte binding molecules to detect specific analyte molecules in a homogenous phase.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: July 26, 2016
    Inventors: Tianxin Wang, Xingxiang Li
  • Purification of triphosphorylated oligonucleotides using capture tags
    Patent number: 9399658
    Abstract: The present invention relates to a method of preparing triphosphate-modified oligonucleotides using a capture tag. The method allows the synthesis and purification of triphosphate-modified oligonucleotides in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: July 26, 2016
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Janos Ludwig, Marion Goldeck, Brian Sproat
  • Certain chemical entities, compositions, and methods
    Patent number: 9399659
    Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: February 18, 2015
    Date of Patent: July 26, 2016
    Assignee: SUZHOU NEUPHARMA CO., LTD
    Inventor: Xiangping Qian
  • N-substituted indenoisoquinolines and syntheses thereof
    Patent number: 9399660
    Abstract: N-Substituted indenoisoquinoline compounds, and pharmaceutical formulations of N-substituted indenoisoquinoline compounds are described. Also described are processes for preparing N-substituted indenoisoquinoline compounds. Also described are methods for treating cancer in mammals using the described N-substituted indenoisoquinoline compounds or pharmaceutical formulations thereof.
    Type: Grant
    Filed: April 28, 2015
    Date of Patent: July 26, 2016
    Assignees: Purdue Research Foundation, NATIONAL INSTITUTES OF HEALTH (NIH)
    Inventors: Mark S. Cushman, Yves George Pommier, Peng-Cheng Lu, Christophe Marchand, Keli Agama
  • Tetrapeptide copper catalysts capable of oxidizing hydrocarbons at room temperature
    Patent number: 9399661
    Abstract: The present invention relates to peptide copper catalysts capable of oxidizing hydrocarbons at room temperature.
    Type: Grant
    Filed: July 31, 2015
    Date of Patent: July 26, 2016
    Assignee: University of The West Indies
    Inventors: Gurdial Singh, Latisha Candice Nicholas-Lewis
  • Concurrent chemotherapy and immunotherapy
    Patent number: 9399662
    Abstract: The concurrent administration of chemotherapy and immunotherapy has been considered a contraindication because of the concern that the induced lymphopenia would ablate therapeutic efficacy of immunotherapy. Temozolomide has been shown to be an effective chemotherapeutic for patients with malignant gliomas and to deprive patients with glioblastoma (GBM) patients of this agent in order to treat with immunotherapy is controversial. Despite conventional dogma, we demonstrate that both chemotherapy and immunotherapy can be delivered concurrently without negating the effects of immunotherapy, hi fact, the temozolomide induced lymphopenia may actually be synergistic with a peptide vaccine.
    Type: Grant
    Filed: November 2, 2006
    Date of Patent: July 26, 2016
    Assignees: Duke University, Board of Regents, The University of Texas System
    Inventors: John H. Sampson, Darell D. Bigner, Duane Mitchell, Amy Heimberger
  • Competitive inhibitor of GP120
    Patent number: 9399663
    Abstract: Peptides and peptide analogs that competitively inhibit HIV protein gp120 and methods for making and using the same.
    Type: Grant
    Filed: February 24, 2015
    Date of Patent: July 26, 2016
    Assignee: Georgetown University
    Inventors: Italo Mocchetti, Valeriya Avdoshina
  • Process for purification of pneumocandin
    Patent number: 9399664
    Abstract: The process described herein discloses purification process of a secondary metabolite produced by fermentation route. The process involves selective removal of impurities at various stages of washings, charcoalization followed by crystallization. The product is closely related to class of echinocandins and is found to be potent antifungal compound & a key ingredient in the synthesis of antifungal drugs.
    Type: Grant
    Filed: May 17, 2010
    Date of Patent: July 26, 2016
    Assignee: Biocon Limited
    Inventors: Kushal Rastogi, Onkar Prakash Santan, Nitin Sopanrao Patil, Rakesh Bhaiyyaram Mendhe
  • Composition for preventing or treating cervical cancer having human papillomavirus plasmodium and immunity enhancer
    Patent number: 9399665
    Abstract: A composition for preventing or treating cervical cancer comprising a human papillomavirus plasmodium and an immunity enhancer is provided. A fusion protein including a fusion polypeptide recombined to transform a 3D structure of E6 and E7, which are antigens against types 16 and 18 human papillomavirus (HPV), a signal peptide for secreting the fusion polypeptide outside the cells and an immunity enhancer peptide present in an individual is also provided. The fusion protein may be useful in treating HPV-triggered tumors by inducing an immune response specific to the antigens against the HPV types 16 and 18.
    Type: Grant
    Filed: March 3, 2015
    Date of Patent: July 26, 2016
    Assignee: GENEXINE, Inc.
    Inventors: Young Chul Sung, Sang Hwan Seo, You Suk Suh
  • Inhibiting interaction between the HIF-1ALPHA and p300/CBP with hydrogen bond surrogate-based helices
    Patent number: 9399666
    Abstract: The present invention relates to peptides having one or more stable, internally constrained ?-helices, and that include a sequence that mimics at least a portion of the C-terminal transactivation domain of HIF-1?. Also disclosed are pharmaceutical compositions containing these peptides and methods of using these peptides, for example to reduce gene transcription, treat or prevent disorders mediated by interaction of HIF-1? with CREB-binding protein and/or p300, reduce or prevent angiogenesis in a tissue, induce apoptosis, decrease cell survival and/or proliferation, and identify potential ligands of CREB-binding protein and/or p300.
    Type: Grant
    Filed: September 18, 2009
    Date of Patent: July 26, 2016
    Assignees: New York University, The Arizona Board of Regents on Behalf of the University of Arizona
    Inventors: Paramjit S. Arora, Bogdan Olenyuk, Ross N. Chapman, Laura Henchey, Katherine M. Block